Oxair PSA systems boost oxygen supplies as Covid-19 cases continue to rise

As Covid-19 cases continue to increase across the globe, advanced gas process system manufacturer Oxair is offering its oxygen pressure swing adsorption (PSA) to those who need a continuous oxygen supply.

With continuing worries surrounding oxygen supply, the Australia-based company with its manufacturing facility in Australia and India can turn around orders for ready-to-use, standalone oxygen PSA units in about eight to ten weeks, depending on local lockdown laws or travel restrictions.

A key piece of equipment in the fight against Covid-19, PSA oxygen offers patient care with a permanent flow of high-quality oxygen – in Oxair’s case a plug and play system with output pressure of four bar and a flow rate to suit the needs of the hospital.

The system delivers constant oxygen of 94-95 percent purity through PSA filtration, a unique process that separates oxygen from compressed air. The gas is then conditioned and filtered before being stored in a buffer tank to be used directly by the end user on demand.

“We are ready to step up supplies and prepared to do whatever is necessary to help healthcare services during the current coronavirus crisis - and beyond - by providing this life-saving oxygen equipment wherever it is needed,” said David Cheeseman, Chief Engineer at Oxair.

“The design of these PSA systems as ‘plug-and-play’ means that they are literally ready to start working as soon as they are delivered and plugged in – with voltage adapted to the country of delivery. So hospitals can rely on technology which is tried and tested over many years, coupled with almost instant access to vital oxygen supplies.”